ChemoCentryx to Host Virtual R&D Day on April 14, 2021
April 07, 2021 08:30 ET | Source: ChemoCentryx, Inc. ChemoCentryx, Inc. Mountain View, California, UNITED STATES
MOUNTAIN VIEW, Calif., April 07, 2021 (GLOBE NEWSWIRE) ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that it will host a virtual R&D Day on Wednesday, April 14, 2021 beginning at 12:30 p.m. ET. The event will feature a panel of key opinion leaders, a testimonial from a patient living with ANCA-associated vasculitis and members of the ChemoCentryx Management team. The event will focus on the Company’s upcoming milestones and developments in key pipeline programs.
Presenters:
Tausif (“Tosh”) Butt, Executive Vice President and Chief Operating Officer of ChemoCentryx
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Yumanity Therapeutics Announces Study Demonstrating In Vivo Efficacy of YTX-7739 in a .
Yumanity Therapeutics IncApril 6, 2021 GMT
YTX-7739 demonstrates efficacy, including increased median overall survival, both as a single agent and in combination with temozolomide, the standard-of-care for GBM
Shared therapeutic target with Parkinson’s disease expands potential utility of
YTX-7739 to non-neurodegenerative diseases
SNO/NCI Joint Symposium: Targeting CNS Tumor Metabolism
BOSTON, April 06, 2021 (GLOBE NEWSWIRE) Yumanity Therapeutics (NASDAQ: YMTX), a biopharmaceutical company focused on the development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced results of a study that demonstrate
Vaccitech Appoints Joseph Scheeren, PharmD, to its Board of Directors globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs Through .
Vaccitech LimitedMarch 17, 2021 GMT
OXFORD, United Kingdom, March 17, 2021 (GLOBE NEWSWIRE) Vaccitech Ltd (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announces that it has raised $168 million in a Series B financing. This includes $43 million in convertible loan notes previously issued by Vaccitech that converted into Series B shares.
The Series B financing round was led by M&G Investment Management (part of M&G plc), with further participation from new investors including Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund, and Future Planet Capital among others. The Series B financing round was also support
NEW YORK, Feb. 17, 2021 Intra-Cellular Therapies, Inc. , a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system . | February 21, 2021